Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.89 |
| ▸ | RAB9A | P51151 | 7/20 | 0.89 |
| ▸ | ATM | Q13315 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065565 | 1.00 | NPC1 (0.89) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL8460601 | 0.94 | NPC1 (0.80) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL7177042 | 0.94 | NPC1 (0.80) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL8555112 | 0.89 | NPC1 (0.72) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL16604283 | 0.89 | NPC1 (0.76) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL8341109 | 0.88 | RAB9A (0.72) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL14082224 | 0.86 | NPC1 (0.72) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL17675306 | 0.86 | NPC1 (0.72) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL2862565 | 0.86 | NPC1 (0.68) | NPC1RAB9AATMALDH1A1SMN1; SMN2 | |
| SCHEMBL23015752 | 0.85 | RAB9A (0.67) | NPC1RAB9AATMALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | claimed |
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | claimed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | claimed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | claimed |
| US-20240024314-A1 | Methods of Treating Splenomegaly | TELIOS PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-11642343-B2 | Methods of treating splenomegaly | TELIOS PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220184069-A1 | METHODS OF TREATING SPLENOMEGALY | TELIOS PHARMA, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| CN-113735850-A | Synthesis method of 1,2, 4-triazole compound | 河南师范大学 | 2021-12-03 | — | — | CN | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105481-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | NPC1 3212/4885RAB9A 1291/4885ATM 4021/4885 |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | NPC1 3690/4885RAB9A 2681/4885ATM 86/4885 |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | APEH, ARSA, DNPEP | NPC1 3337/4885RAB9A 1777/4885ATM 2224/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NPC1 1758/4885RAB9A 2076/4885ATM 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.